Moreover, because NIVO monotherapy has similarly been shown to increase CD8+ TILs as well as PD-L1 expression on tumors in multiple tumor types14–16, including melanoma14,15, it is difficult to determine the contribution of BEMPEG when used in combination with NIVO from the results of PIVOT-02. The gene discussed is CD8A; the disease is neoplasm.